Years Ahead in HIV Prevention Research

Time to Market

Prevention Product	Q1 Q2 Q3 Q4 Q1	2023 2024 2025 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4	2026 2027 2028 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Vaginal Ring	Dapivirine monthly Multiple regulatory approvals WHO Guidelines	Multiple implementation science projects Selected Global Fund procurement and progra	 Demonstrated modest efficacy Unclear demand and limited initial supply Initial price ~\$180/yr Oct 2023: A memorandum of understanding reached on a product license with Kiara 3-monthly ring currently in development and could be
Long-Acting Injectables	Cabotegravir One intramuscular injection (3ml) every 2 months WHO Guidelines	Selected Global Fund and PEPFAR procurement	regulatory submission by 2027 • 4-monthly formulation currently in development, with
	Lenacapavir Two subcutaneous injections (1.5 ml each) every 6 months Phase 3: PURPOSE	Phase 2: PURPOSE 3, 4, 5 and EMA; others pending	Possible Dec 2024: Global Fund & PEPFAR commit to reaching 2
Oral PrEP	F/TAF daily Phase	Possible regulato approva	regulatory submission expected in 2027
	MK-8527 monthly		EXPrESSIVE-10 launched in Q3 20205, and IVE-11 expected to launch in Q4 of 2025



Dual Prevention Pill

Co-formulated
TDF/FTC and
ethinyl estradiol/
levonorgestrel
oral contraceptive
pill
daily

Pilot bioequivalence (BE) study



Possible regulatory approvals

Possible product introduction

Acceptability Study: HPTN 104